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1. Introduction 
Ninety elements occur naturally on earth. Out of these, nine are radioactive and among the 
remaining eighty one that could support life, sixty one are metals. Our bodies are 3% metal. 
Thus, it is surprising that some of the most serious challenges to human life, externally, the 
pollutants cadmium, mercury and lead are attracting more attention, whereas internally, 
there is a constant battle against sodium and calcium that are rejected by cells and 
accumulated elsewhere in the body during the ageing process. Furthermore, some diseases 
release metals into the blood stream. Their use in the fight against diseases was first 
described by Schubert in 1965. Man just like other vertebrates requires cations of the metals 
to facilitate a great many essential life processes. Moreover, many of the metals are essential 
for all other forms of life process. Around 5000 years ago the Egyptians used copper metal to 
sterilize water and gold was used in a variety of medicines in Arabian and China, but the 
practice emanated from the value of pure metal rather than from therapeutic effects.  
Metals have played an important role in medicine for years, ever since human being started 
to walk on the planet. Many are essential to our diets in varying quantities, although people 
have only recently realized their significance.  
This could probably be attributed to our increased awareness of personal and family health. 
Most of the major classes of pharmaceutical agents contain examples of metal compounds 
which are in current clinical use. Inorganic compounds (metal complexes) have been used to 
treat various diseases and ailments for many centuries. 
Introducing metal ions into a biological system may be carried out for therapeutic or 
diagnostic purposes, although these purposes overlap in many cases. Yet despite the 
obvious success of metal complexes as diagnostic and chemotherapeutic agents, few 
pharmaceutical or chemical companies have serious in-house research programs that 
address these important bioinorganic aspects of medicine. Metals not only provide 
templates for synthesis, but they also introduce functionalities that enhance drug delivery 
vectors. It should be recognized that traditional studies of inorganic drugs at a fundamental 
level are not complete without a program on metal pharmacology. Many organic drugs 
require interaction with metals for activity. They interact with metals at their target site or 
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during their metabolism or disturb the balance of metal ion uptake and distribution in cells 
and tissue. The unique properties of metal complexes tend to offer advantages in the 
discovery and development of new drugs. The metal complexes are amenable to 
combinatorial synthetic methods, and an immense diversity of structural scaffolds can be 
achieved. Metal centers are capable of organizing surrounding atoms to achieve 
pharmacophore geometries that are not readily achieved by other means. Additionally, the 
effects of metals can be highly specific and can be modulated by recruiting cellular processes 
that recognize specific types of metal-macromolecules interactions.  
Understanding these interactions can lead the way towards rational design of metallo-
pharmaceuticals and implementation of new co-therapies. Metal complexes appear to 
provide a rich platform for the design of novel chemotherapeutic drugs. We can choose the 
metal itself and its oxidation state, the numbers and types of coordinated ligands and the 
coordination geometry of the complexes. The ligands can not only control the reactivity of 
the metal, but also play critical role in determining the nature of secondary coordination-
sphere interactions involves in the recognition of biological target sites such as DNA, 
enzymes and protein receptors. Also the ligands themselves can sometimes undergo 
biologically-important redox reactions or other modifications(e.g hydrolysis) in vivo 
mediated by the metal. These variables provide enormous potential diversity for the design 
of metallodrugs. Metal-ligand (coordination) bonds are usually much-weaker than covalent 
bonds and so ligand substitution reactions will be common in biological media. Most 
metallodrugs are therefore, pro-drugs. They can undergo ligand substitution and redox 
reactions before reaching the target site. A displaced ligand may itself attack a target site 
and controlled ligand release can play a role in the mechanism of action. The ongoing battle 
against resistance of organism towards drugs is far over. The importance of developing new 
drug chemotherapeutic drugs cannot be over emphasized. This trend was in the past 
intiated by the successes of metal-containing antitumor drugs such as cisplatin. Over the last 
four decades thousand of Inorganic drugs have been screened for their medicinal activity in 
a wide range of diseases, but only a handful have made it into the clinic. 
Huge success was achieved in the area of anticancer drugs and antimicrobial drugs. Some of 
the metal-based drugs already in market are cisplatin (anticancer drug), cardolite 
(myocardial imaging agent drug), silverderma (skin burn drugs marketed in spain by Aldo 
Union), flammazine (Skin diseases drug marketed by Durpha) and Matrix metalloproteinase 
inhibitors (cancer and inflammatory disease marketed by British Biotech). The main 
objective of this paper is to review some of the previous work done by researchers with the 
hope of shielding light on the need to develop new drugs. We shall also draw together some 
of the work carried out by our group within our laboratories in the field of metal-containing 
Antibacterial agents. 
2. Resistance of drugs 
One way of restoring the activity of organic drugs for which resistance has emerged is to 
modify the structure to contain a metal, and some of these compounds are metal complexes. 
As early as 1975, it was reported by Edwards et al, (1975) that substituting the aromatic groups 
in the antibiotics penicillin and Cephalosporine with ferrocenyl moieties produced 
compounds with altered antibacterial activity compared to the starting materials Against 
various strains of Staphyloccus aureus, ferrocenyl penicillin showed comparable activity to 
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benzyl-penicillin and also β- lactamase, which is one of the enzymes responsible for bacterial 
resistance to penicillin-type antibiotics. Many synthetic drugs have been discovered over the 
years for the treatment of malarial disease like chloroquine, sulphadoxine and pyrimethamine 
being among the most effective. However, malarial parasites resistant to these drugs are now 
widespread in America, Asia and Africa. Resistance to antimalarial drugs first to chloroquine 
and then to others was first noticed in the 1950s and since then, it has spread all over the 
world. Resistance of Plasmodium falciparum to chloroquine has become a major health concern 
of developing world. Therefore, it becomes highly necessary to come up with alternative 
antimalarial drugs with different structures and mode of action to deal with the development 
of resistance to the drugs in current use. Many researchers worked extensively on discovery of 
new therapeutic drugs to combat this problem of resistance. A number of papers on 
modification of the structure of the existing antimalarial drugs by incorporation of metals into 
their molecular structure appeared in literature. Notable among them are those of (Spacu et 
al,1968; Wasi et al,1987 ; Hubel et al, 2000; Biot et al,1999; Navarro et al, 2001; Sanchez-Delgado 
et al, 1993 and Tsangaris et al, 1974, Biot et al.2000) 
Majority of these complexes were found to possess higher antimalarial activities than their 
parent drugs. The most recent and remarkable is the work carried out by Biot and co-workers. 
They inserted ferrocene(organometallic compound) into molecular structure of some 
antimalarial drugs.There is strong evidence that significant structural change to the side chain 
either through altering its length or through the introduction of more structural motifs such as 
ferrocene circumvents chloroquine resistance. Since the parasite needs iron for its development 
inside the red blood cells. Attempt was made by Biot et al, (1999) to insert a ferrocenyl group 
into the side chain of chloroquine, thus, producing a hybrid compound called Ferroquine 
(Figure 1). They combined poison (chloroquine) and bait (ferrocene) in the same molecule.  
 
Fig. 1. Ferroquine 
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Ferroquine synthesized by them was found to be much more potent in mice than chloroquine. 
Tests have shown that ferroquine is active against both chloroquine sensitive and chloroquine 
resistant strains of Plasmodium and that it is safe and effective in mice, as well as being non-
mutagenic. It was discovered that even when resistance to the drug builds up in mice, it can be 
reversed. The complex is a good candidate for further development. It is a promising 
organometallic analog of chloroquine.. 
They also used the same strategy to incorporate ferrocene into mefloquine. The pathway 
used for the synthesis of the ferrocenic mefloquine(Figure 2) includes coupling of an 
aminomethyl substituted ferrocene carboxaldehyde with a lithioquinoline compound. 
Mefloquine is covalently linked to a substituted ferrocenyl unit. The complexes exhibited a 
broad strong hydroxyl absorption band (3000cm-1) characteristic of a hydroxyl group 
coordinated to an iron atom.(Biot et al. 2000). 
The 1H-NMR and mass spectra of the two diastereoisomers of the complex were similar 
except for the resonance of the Fe-CH-OH proton. The resonance of diastereomer (A) 
appeared at 8-6.5ppm (singlet, 1H) and resonance of diastereomer (B), appeared at 8 – 6.2 
ppm due to a different aniosotropic zone of ferrocenic skeleton. 
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Fig. 2. Ferrocenic mefloquine 
Artemisinin ferrocenic complexes were synthesized by Delhaes et al (2000). Novel ferrocenic 
artemisinin derivatives were found potent as artemisinin (QHS). Their antimalaria activity 
and affinity to bind with Ferritoporphyrin (IX) were studied. All the compounds showed 
capacity to bind with ferritoporphyrin (IX) resulting from the addition of different drugs 
concentrations. The association stoichiometry of compounds to Ferritoporphyrin (IX) was 
found to be 1:2. 
Our research group also contributed to efforts being made to search for novel 
chemotherapeutic drugs against the resistant strains of Plasmodium falciparum. The synthetic 
strategy involves enhancing the activity of antimalarial drugs through the incorporation of 
transition metals into their molecular structures. In 1997, Obaleye and Nde-aga reported the 
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preparation and characterization of amodiaquine hydrochloride and chloroquine complexes. 
They reported that Amodiaquine HCI coordinated through O-H and N-H to the metal ion and 
chloroquine coordinated to the metal ion through (N-H), (C-N) and (C=N) functional groups 
acting as either a bidentate or tridentate ligand. All the complexes possessed antimalarial 
activity as confirmed by studies on mice infected with Plasmodium yoelli. Obaleye et al (2009) 
carried out in vivo antimalarial activities and toxicological studies of some quinoline methanol 
metal complexes. Antimalarial activities of these complexes were investigated using mice 
infected with Plasmodium berghei. The results showed that four of the metal complexes 
[(MefH+)2Fe(SO4)2]2-, (MeFH+)CuCl4.4H2O, [Fe(QUIN)Cl2.H2O]SO4.3H2O (Figure 3) and 
[Zn(QUIN)ClSO4 ]∞ exhibited significant higher antimalarial activity (P<0.05) than 
chloroquine and their parent ligands respectively.  
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Fig. 3. Structure of [Fe(QUIN)Cl2.H2O]SO4.3H2O  
The effects of these complexes on alkaline phosphatase (ALP) activity of kidney, liver and 
serum of Albino rats were investigated. Based on the results obtained, the complexes were 
found to be non-toxic and possess better antimalarial activity than the conventional 
antimalarial chloroquine. Tella and Obaleye (2010) synthesized two metal complexes of 
Co(II) and Cd(II) Trimethoprim. A distorted tetrahedral geometry is suggested for their 
structures (figure 4) and Trimethoprim behaves as a monodentate ligand. 
The metal binds through the pyrimidine N(1) of the ligand. The complexes have been 
screened for antiplasmodial activity against plasmodium berghei and the results show that 
they are less active than the parent ligand. Toxicological study was carried out by 
investigating the effect of administration of the complexes on Alkaline phosphatase activity 
of kidney, liver and serum of Albino rats and they were found to be nontoxic. It can be seen 
from these studies by our group that incorporation of metal into molecular structure can 
either enhance the antimalarial activity or less or even make it the same.  
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M= Co(II) or Cd(II) 
Fig. 4. Structure of Trimethoprim metal complexes 
Similarly, many organic drugs used to treat the parasitic diseases leismaniasis and chagas 
disease, as well as those used to treat helminth worm infections are becoming increasingly 
ineffective due to drug resistance. Leishmania donovani, which causes Leismaniasis, 
transferred via bite of a sandfly, infects approximately 10-15 million people worldwide. The 
disease may be fatal if not treated and effectivity of traditional organic drugs such as 
Pentamidine, Amphotericin B, Aminosidine and Antimonials is declining due to drug 
resistance (Ashford et al,1992; Quellette et al,1993). Pentamidine one of the organic 
antiparasitic drugs, has been complexed to several different metal centres and its activity 
has been evaluated against different parasite species. Of these an Organo-osmium derivative 
was found to have a 7.5 fold higher therapeutic index than pentamidine alone in treating 
leishmaniasis curing infected mice in a single dose(Loiseau et al,1992; Zinsstag et al,1991; 
Mesavalle et al,1993). 
3. Anticancer metal complexes 
Metal-based drugs are the most widely used drug in chemotherapy. The gallium, titanium 
salts have been shown to have anti-cancer activity. In the mid-1960s, Bernett Rosenberg and 
his co-workers(1965) serendipitously discovered that cis-dichlorodiammineplatium(II) (cis-
[Pt(NH3)2Cl2], cisDDP, cisplatin) exhibited antitumor activity but trans isomer, trans-
[Pt(NH3)2Cl2], did not. Cisplatin, (cis-[PtCl2[(NH3)2] also known as cis-DDP (Figure 5) is 
perhaps the best known example of a small molecule metal-containing drug. The history of 
the discovery and development of Cisplatin remains a remarkable scientific story. Its use 
and effectiveness in cancer chemotherapy since entry into the clinic in the late 1970s has 
been thoroughly documented (Lipport, 1999; Kelland et al, 2000; Wong and 
Giandomenico,1999). Cisplatin is cited for treatment of germ-cell cancers, gestational 
trophoblastic tumors, epithelial ovarian cancer and small cell lung cancer as well as for 
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palliation of bladder, cervical, nasopharyngeal, esophageal, head and neck cancers. 
Cisplatin is a truly remarkable drug, in that for the last 30 years, it has been used to treat 
more than 70% of all cancer patients. 
Pt
H2N
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Cl
 
Fig. 5. Structure of cisplatin 
Despite this success, there is still a limited range of tumors sensitive to cisplatin 
intervention. Some cancers are inherently resistant (O’ Dwyer et al, 1999; Highley et al,2000). 
Due to this shortcomings, the second- generation compounds based on the cisplatin 
structure were developed in an attempt to improve toxicity and/or expand the range of 
useful anticancer activity. Carboplatin entered the clinic in 1998, principally in response to 
the necessity to reduce the toxic side effects of the parent drug(Christian, 1992). Despite the 
lower toxicity,carboplatin is essentially active in the same set of tumors as cisplatin and a 
broader spectrum of activity is not indicated. The problem associated with the use of 
cisplatin have driven the development of new inorganic anticancer therapies such as 
medaplatin and oxaliplatin(Van Rijt and Sadler, 2009). Progress to develop many 
chemotherapeutic transition metals drugs has been quite slow. Metallocenes and 
metallocene dichloride are potential candidates e.g. Titanocene compound (TiCl2Cp2). 
Titanocene dichloride was first recognized as an anticancer agent by Koepf and Koepf-
Maier, (1979) and until recently being evaluated for activity against cisplatin resistant 
ovarian and metastatic renal-cell carcinomas (Clarke et al, 1999).The drug seems to bind to 
the protein in a similar way to iron, resulting in the cylopentadienyl ligands being released 
(Guo et al, 2000) and allowing the titanium metal to be delivered to the cancer cells. 
Titanocene dichloride demonstrates general anti-proliferation activity and has been shown 
to be effective against five types of cancer cells(Koepf-Maier and Koepf, 1987). Other 
metallocenes have more specific activity for example ferrocifens. Ferrocifens (Figure 6) was 
synthesized by Jaouen and Co-workers in 1994. They inserted ferrocene into molecular 
structure of Tamoxifen. Tamoxifen in form of its active metabolite hydroxyltamoxifen, is 
widely used in cancer hormone therapy and belongs to a class known as the Selective 
oestrogen receptor modulators (SERMS). It was discovered 20 years ago. It is used at all 
stages of the disease and recently, it has been shown to have a role in the prevention of 
cancer. It is however, only effective in 60% of cases and can cause problem of resistance 
when used for long time. Tamoxifen also increases the risks of endometrial (uterine) cancer 
and blood clotting in the lungs. Due to these shortcomings, Jaouen and co-workers in 1994 
developed new SERMS that are as active as tamoxifen against as many types of breast 
cancer as possible. In order to find alternative SERMS, they decided to attach metallocenes 
to tamoxifens with the hope of improving its effect(Jaouen et al, 2000) 
One series of Ferrocifens was made by replacing the aromatic phenyl in the β position of 
tamoxifen with an aromatic ferrocenyl of slightly greater bulk and lipophilicity, ferrocifen 
was synthesized via Mc-Murry coupling reaction. Ferrocifens has higher antiproliferative 
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effect against (ERα - and ERβ +) breast cancers than tamoxifen. The process of conversion is 
shown below(figure 6). 
OH 
CH3CH2
OCH2CH2NMe2
Fe
Fe
CH3CH2
OH
O(CH2)nNMe2
 
Fig. 6. Structure of Ferrocifens 
It has been widely reported in the literature that the cytoxic effect of ferrocene complexes 
(Fe2+) is associated with their oxidation to ferricinium type (Fe.3+) radical and O2.– radical. 
Thus, 
Fe2+ + O2 → Fe.3+ + O2.– 
Fe2+ + O2.– + 2H+ → Fe.3+ + H2O2 
Fe2+ + H2O2 → Fe..3+ + OH– + OH. 
O2.– radicals are only slightly reactive towards DNA, but OH. radicals are very reactive and 
provoke various types of lesions, making these radicals highly genotoxic. 
By introducing an organometallic function that liberates OH radicals within the cell via an 
oxidant/antioxidant cascade, we have the SERMS (and possibly for other systems) a 
potential solution to a difficult and essentially paradoxical problem. Combining 
metallocenes with other organometallic centres such as Gold provides another means of 
modifying drug activity and specificity. In this case the complex shows promising activity 
against bladder and colon cancers(Violette et al, 1995). Complexes of group VIIIB metals 
especially Rhodium, Indium and Platinum have been reported to have considerable 
antibacterial activity and induce lysis in Iysogenic bacteria. Platinum II and IV amino halide 
complexes were found to have antitumor activity (Adrien, 1985). Dinuclear Platinum(II) 
complex[Pt2—N,N1—bis(2-dimethylamino oxamide) Cl4] was prepared by reaction of 
K2PtCl4 with the ligand N, N1-bis(2-dimethylamino oxamide) in aqueous solution 
(Messori, et al,2003). X-ray diffraction analysis revealed that the platinum ions 
simultaneously bound to the ligand, on opposite sides. The coordination environment of 
both platinum centers is square planar with identical NOCl2 donor sets. Preliminary  
Tamoxifen     Ferrocifens 
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in vitro studies point out that the dinuclear Platinum complex exhibits significant growth 
–inhibiting properties on a panel of cultured human tumor cell lines, although less 
pronounced than those of cisplatin. 
Several recent studies(Adrien,1985; David, 1972; Messori, et al 2003) investigated twenty 
six inorganic compounds for antiviral and anticancer activity. These included metal 
complexes of already established anticancer drugs such as six mercaptopurine. It was 
suggested that the transfer of metal ion from the ligand to the viruses associated with 
cancer was a mechanism for releasing the anticancer drug in the locality of the tumor. 
Metal chelates of dl- methonine and ethionine were prepared, antibacterial activity were 
attributed to the ligands that render the metal ion fat soluble and thus made it capable of 
acting within the cell(Adrien, 1985).  
Komeda et al (2000) reported another four azole bridged dinuclear platinum(II) 
complexes. All the four complexes were found to show much higher cytotoxicity than 
those of cisplatin.  
4. Anti-inflammatory agents 
Metal complexes of organic drugs have also been used as anti-inflammatory and anti-
arthritic agents. Extensive research is being conducted into Au, Cu and Zn anti-
inflammatory drugs that have fewer side effects with similar or higher efficacy than the 
parent organic drugs commonly in use. Gold compounds were first used in 1929 by 
French doctors to treat rheumatold arthritis(Shaw, 1999; Snyder et al,1987) and remain 
important in the treatment of rheumatic diseases. Several injectable transition gold 
complexes like sodium aurothiomalate, aurothioglucose and sodium aurothiopropanol 
are used clinically in the treatment of severe cases of rheumatold arthritis. (Rafique et al, 
2010) The developments of orally Auranofin(also known as Ridaura was a major 
improvement over the early ‘’injectable gold” preparation which were polymeric). Zhuo et 
al, (2000) and Sorenson,(1976) reported the synthesis and characterization of anti 
inflammatory Zn(II) and Cu(II) complexes of indomethacin. The studies were undertaken 
in order to reduce the side effects associated with the clinical use of indomethacin and 
related carboxylate–containing nonsteroidal anti-inflammatory drug (NSAID). NSAID 
drug exhibits favorable anti-inflammatory, analgesic and antipyretic properties, but it has 
undesirable side effects of inducing gastro-intestinal ulceration and haemorrhages. The 
complexes of indomethacin are superior to uncomplexed indomethacin for treatment of a 
range of conditions and most importantly reduce considerably lower incidences of gastro-
intestinal damage. 
Investigation of anti-inflammatory activity of complexes of diclofenac was carried out by 
Kovala-Demertzi et al,2000, 2001). Diclofenac is one of the widely used non-steroidal anti-
inflammatory drugs (NSAIDs.) The Binuclear copper(II) complex of diclofenac 
[Cu(L)2(H2O)]2. 2H2O was found to have an anti-inflammatory profile superior to diclofenac 
when inhibiting inflammations due mainly to the activation of lipooxygenase and or to the 
complement systems. Other metal complexes of diclofenac synthesized by this group are 
Co(II), Ni(II) and Pd(II). These complexes exhibit a superior anti –inflammatory profile, 
inhibiting inflammations and phagocytosis and act as antioxidant compounds, properties 
that are absent in diclofenac. 
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The group also synthesized and characterized organotin complexes of Diclofenac 
(Kourkoumelis et al., 2003).The complexes were found to be dimeric. The anti-inflammatory 
activity of complexes were not investigated. Extensive work was also carried out on the 
complexation of piroxicam with organometallic compound. Di Leo et al, 1998 synthesized 
Platinum(II)-piroxicam (Figure 7) complex by reaction of ziese salt K(PtCl2)(η2-C2H4).H2O 
with piroxicam in ethanol. The complex PtCl2)(η2-C2H4).(Hpir)].0.5C2H5OH- was 
synthesized. Platinum was linked to two chloride ions trans to each other, N(1) atom from 
the pyridyl ring of piroxicam and to an η2-C2H4 molecule. 
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Fig. 7. Structure of Platinum(II)-Piroxicam 
5. Antifungal agents 
Many metal complexes have powerful antifungal activities and and are already in common 
day to day use such as silverderma (Silver complex of sulfadiazine) and Flammazine (Zinc 
complex of silverdiazine.) 
Navarro et al, (2001) synthesized and characterized complexes of Copper (II) and Gold (I) 
with Clotrimazole and ketoconazole. It was found out that the ligands coordinated to Gold 
through imidazole N(1) atom of each ligand with linear structure. The clotrimazole and 
ketonazole coordinated to copper (II) through N (3) of the ligand atom with square planar 
structure. The new compounds were tested for in vitro activity against cultures of 
epimastigotes of trypanosoma cruzi. At concentration equivalent to 10.6M of total clotrimazole 
and ketonazole in dimethylsulfoxide, all the complexes exhibited higher inhibitory activity 
than their respective parental compound. Sanchez-Delgado et al(1993) reported 
enhancement of efficacy of complex of Ruthenium clotrimazole against trypanosome Cruzi as 
compared to clotrimazole ligand. Bankole et al(1979) reported the synthesis of organosilicon 
derivatives of p-aminosalicylic, salicylic and benzoic acids. It was discovered that the 
presence of silicon in the p-aminosalicyclic acid- silicon complex- prolonged and increased 
the antitubercular activity of p-amino salicyclic acid in the body. The reaction scheme for the 
synthesis of p-aminosalicyclic acid silicon complex is shown below (Figure 8). 
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Fig. 8. Structure of Para-aminosalicyclic acid silicon complex 
6. Antihypertensive agents 
Hypertension can be a long term illness and it is becoming increasingly common, severely 
limiting the quality of life of the sufferer. Because of the long term nature of the condition 
and therefore the long term nature of the medication, there is a strong incentive to develop 
drugs that can regulate blood pressure without causing side effects or becoming resistant 
over the course of the treatment. Many of the current leading therapies are based on organic 
drugs, although some inorganic compounds also exhibit excellent activity. 
Anion of Sodium nitroprusside anion can be used to release NO in biological system and 
has been investigated as a potential hypotensive (Tuzel,1974). Sodium nitroprusside can be 
administered by infusion and reduces blood pressure within two months, the effect 
depending on the rate of NO release. Other similar compounds have been studied for 
potential application as vasodilators including vanadium, cobalt and molybdenium 
analogues(Hayton,2002). 
Essien and Coker, (1987) reported the complexation of antihypertensive drug with calcium. 
Calcium nifedipine(Figure 9) was synthesized by reaction of calcium salt with nifedipine. 
The infrared spectrum revealed a strong evidence of possible complexation occurring at the 
carbonyl group (C=O) of the nifedipine. Two atoms of calcium complexed each to one pair 
of C=O groups of 2 molecules of nifedipine.  
Recently, Golcu et al,(2005) carried out the synthesis of binuclear copper (II) complex of 
Antihypertensive drug Pindolol. The biological activity of the parent drug pindolol was 
compared with the complex. The binuclear Cu(II) complex of pindolol was found to be 
highly active against Bacillus megaterium, Aeromonas hydrophilia, Escherichia Coli, Candida 
albicans bacteries and Saccoramyces cerevisia, Rodotorula rubra, Kluyveromyces fragilis yeasts. 
However, the free ligand was found not to be against these bacteria and yeasts. 
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Fig. 9. Structure of Nifedipine – Ca. 
7. Antibiotics agents 
Many metal complexes have powerful antimicrobial activities and some of them are already 
in market.Silver bandages for treatment of burns. 
A lot of antimicrobial metal complexes synthesized by researchers appeared in literature. 
We shall review some of these work. Emphasis will also be laid on the work carried out. 
Behrens et al. (1986) synthesized the transition metal complexes of Nalidixic acid. 
Nalidixic acid is used in the clinical treatment of urinary tract infections caused by gram-
negative bacteria. The mode of coordination of the drug was investigated by spectroscopic 
studies. From the spectra data, nalidixic acid anion binds through the carboxylate group either 
as a chelate or as bridge to give polymeric structure. Zupanicic et al.(2001) synthesized 
[CfH2]2[ZnCl4].2H2O from Ciprofloxacin and ZnCl2 in dilute HCl. The compound was shown 
to be ionic consisting of tetrachlorozincate(II)dianion and two protonated monoatomic 
ciprofloxacin molecules. The second one which is a complex [Cu(Cf)(H2O)3]SO4. 2H2O was 
synthesized by Turel et al.(1999). The complex was prepared by direct reaction of copper 
sulphate pentahydrate with ciprofloxacin in distilled water. X-ray crystallographic studies 
showed that the ciprofloxacin atom is bonded to the metal through carbonyl oxygen and 
carboxylic oxygen atom. Water molecules also coordinated to the copper. 
Obaleye et al. (2001) synthesized and characterized metal (II) complexes of tetracycline HCl 
(Figure 10). For Mn, Fe, Zn, Co and Cd metals, the coordination of the metal to tetracycline 
is through one of the hydroxyl bands of tetracycline and oxygen of the carboxamide group, 
the proposed structures of the complexes were tetrahedral. 
For Ni and Cu, the proposed structure of the complexes (Figure 11) were still tetrahedral, but 
the coordination is via oxygen of the ν(C=O) and hydroxyl band of the drug. By using well –
known antibiotics. Ogunniran et al (2007) complexed Ampicillin Trihydrate,Chloramphenicol 
and Oxytetracycline with Ni(II), Fe(III) and Co(II) chloride salts. Thus, the three ligands acted 
as terdentate. The values of Zone of inhibition for E.Coli, S. Aureus and K.Pneumonas revealed 
enhanced antimicrobial activities upon complexation with metal salts. 
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Fig. 10. Metal complexes Tetracycline [M = Mn, Fe, Co, Zn or Cd (II)]. 
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Fig. 11. Metal complexes of Tetracycline [Cu(II) or Ni(II)]. 
In 2007, Obaleye and co- workers synthesized two iron(II) complexes of ciprofloxacin by 
reaction of the ligand with iron(III) Chloride hexahydrate in different solutions. [Fe(Cip) 
2Cl2]Cl. 6H2O and (H3Cip)FeCl4]Cl. H2O were prepared. The antibacterial activities of the 
products against microorganisms were tested and it was established that their activities 
were comparable with those of their parent drug. Toxicological studies were carried out in 
which therapeutic dose of the ciprofloxacin drug and the metal complexes were 
administered to albino rats and the results showed that the metal complexes are not toxic.  
Attempt was also made to incorporate metal salts into mixed ligands. Cu and Co complexes 
of mixed sulphadiazine-cloxacillin were synthesized and characterized(Tella et al, 2010). 
Infra-red spectra revealed that coordination of the metal to the sulphadiazine is through 
nitrogen of the pyrimidine and sulphonyl groups while in cloxacillin, coordination with the 
metal occurred through the oxygen of the carbonyl group of β- lactam ring. Octahedral 
structure was proposed for the complexes. Antimicrobial screening was also evaluated 
which showed that the complexes exhibit higher activities than their corresponding ligands. 
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Recently, Tella et al,(2011) investigated the possibility of transition metals coupling of 
antibiotics into cellulose. Chelates of Co(II), Zn(II) and Mn(II) cellulose- Antibiotics(Figure 
12) were synthesized to form insoluble immobilized matrix with antibiotics. It can be 
established from this study that it is possible to form active immobilized antibiotics by 
simple chelation with metal salts.  
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Fig. 12. Metal cellulose-Antibiotics Chelates. 
From the antibacterial studies carried out, the products  might be of greater applicability as 
food packaging material, antibacterial surface(water storage tanks, industrial membranes 
and chromatographic columns).. 
8. Antibacterial agents 
Casanova et al. (1993) synthesized single-crystal complex of [Zn (sulfathiazole)2] H2O. The 
sulfathiazole was found to act as a bidentate ligand, chelates to two Zn ion as a bridge 
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through the N thiazole and N amino atoms. Rudzinski et al (1982) prepared several 
Sulfonamide –schiff base complexes of selenium(IV)(Figure 13) and tellurium(IV) 
(Figure14). Selenium coordinated through azomethine nitrogen, hydroxyl oxygen of the 
sulphonamide schiff base with chloride ion of the selenium salt to complete octahedral 
structure, while tellurium coordination site is only azomethine nitrogen, with chloride ion of 
the tellurium salt to complete the octahedral structure. 
CH = N 
O
H
Se
Cl
Cl
SO2NH2 SO2NH2
N = NC R2
R2
Cl
 
Fig. 13. Selenium (IV) sulphonamide Schiff base complex 
The complexes were found to be active against bacterial even better than the parent ligand.  
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Fig. 14. Tellurium (IV) sulphonamide Schiff base complex 
These two complexes proved to be biologically active as evidenced by pharmacological 
tests. Garcia–Raso et al (2000) synthesized single crystal of zinc-sulfamethoxazole complex 
[Zn(sulfamethoxazolato)2 (pyridine)2 (H2O)2](Figure15).  
 
A Search for Antibacterial Agents 
 
212 
H2N N 
N 
CH3
S
O 
O 
O
H2O 
Zn 
Pyridine 
OH2Pyridine 
H2N 
N 
I
H
CH3S
O 
O 
N O  
 
Fig. 15. Zinc sulfamethoxazole complex 
The geometry around Zn(II) ion can be described as a slightly distorted compressed 
octahedron. Two pyridine and two isoxazole N atoms are located in the equatorial plane 
and two oxygen atoms of two water molecules are placed in the apical positions. 
Ajibade and Kolawole, (2008) reported trivalent complexes of sulphadiazine. The complexes 
were tested for in-vitro activity against cultures of the resistant strains of Plasmodium 
falciparium, Tripamastigotes T.B. rhodesiense and Amastigotes L. donovani to determine their 
antiprotozoa activities. The Fe(III) complex is more active than the other complexes against 
the parasitic protozoa. 
Recently, our group studied mode of coordination and Antimicrobial activities of complexes 
of some sulphonamides. Tella and Obaleye(2009) synthesized five complexes of copper (II) 
4,4-diaminodiphenylsulphone (Dapsone) using copper salts of counter ion(sulphate, nitrate 
and chloride) in different reaction media(Solvents). The structure of the compounds were 
elucidated by spectroscopic techniques. Dapsone coordinated to the metal in monodentate 
and bidentate manner. with all the complexes having tetrahedral structures (Figures 16 and 
17) 
The biological activities data showed that the complexes are more active against Escherichia 
coli, Klebbsiella pneumonia and staphylococcus aureus than the free ligand. 
Antimalarial activities of the complexes and the ligand were investigated using mice 
infected with Plasmodium berghei. All the complexes exhibited lower activity than the ligand 
and chloroquine. Toxicological studies carried out showed that the complexes are not toxic, 
as indicated from the effect of administration of the complexes on alkaline phosphatase 
activities of kidney, liver and serum of Albino rats. The serum ALP activity showed no 
significant change(P>0.05), suggesting non-damaging effect on the plasma membrane of 
liver and kidney cells. 
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Fig. 16. Structure of [Cu(DAP)2Cl2 ](CH3OH)2 
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Fig. 17. Structure of [Cu(DAP)(NO3)(H2O)]NO3 
Metal complexes of sulphadimidine synthesized by Tella and Obaleye (2009) were 
established to possess higher antibacterial activities than the ligand. The complexes showed 
greater activities against the Escherichia coli, Klebbsiella pneumonia and staphylococcus aureus. 
This is in agreement with the findings of other researchers.  
9. Vitamin metal complexes 
Vitamins are essential for the normal growth and developments of a muticellular organisms. 
Once growth and development are completed, vitamins remain essential nutrients for the 
healthy maintenance of cells, tissues and organ that make up a multicelluar organisms. It 
has been established that complexation of metal with vitamins enhances the activity of the 
vitamins. Many workers made attempt to synthesis metal complexes of thiamine. From 
early complexation studies, it was evident that thiamine and its derivatives do not readily 
form true complexes with direct metal-thiamine bonds but instead, they give ionic salts 
mainly of the type (HT)2+(MX 4)2- due to the net positive charge on the thiazolium ring and 
the easy protonation of pyrimidine N(1) atom. Such ionic salts synthesized by them  
are [ThH]2+ [HgCl3]2-, [ThH]2+[CdCl4]2- and [ThH]2+ [HgCl4]2-. (Garcia-Raso et al, 2000, 
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Richardson,1975). However, the successful preparation and structure determination  
of Cd(Th)Cl3.O.6H2O,Cd(Th) Cl3]2.2H2O, Cu(Th) Cl2, Zn(Th) Cl3. O.4H2O (Hadjilias, 1983; 
Gramer,1984; Bencini,1987) proved that metal-thiamine complexes exist. Another study on 
vitamin is the work carried out by Mosset et al(1978). They synthesized Cd(Py)Cl2 from 
reaction of aqueous solution (pH=6.5) of equimolar amount of pyridoxine and cadmium 
chloride. From NMR and X-ray structural studies, the structure consists of infinite chains of 
Cd-bridge-Cd. The Cd atom, in an octahedral environment is bound to three chlorine atoms 
and three oxygen atoms of the ligand. Two chloride ions make a double bridge between two 
equivalent cadmium atoms. The pyridoxine molecule acts as a bidentate ligand through two 
oxygen and as a bridge between two equivalent atoms. Zinc complex of pyridoxine was also 
reported by Thompson et al(1980). [Zn(Py)2(H2O)2](NO3)2 was synthesized from reaction of 
zinc nitrate and pyridoxine. The X- ray crystallographic studies revealed that Zinc atom lie 
on centers of symmetry and are chelated to the 4-amino methyl and phenolate groups of 
pyridoxine zwitterions. Octahedral coordination is completed by water molecules. Dakovic 
et al (2008) reported the synthesis of nicotinamide metal complexes of Zn(II) and Hg(II). The 
nicotinamide with carboxamide group in the meta-position to the pyridine nitrogen atom 
acts as a monodentate –N ligand for the zinc(II) and mercury (II) ion coordinating to metal 
ions through the pyridine nitrogen atom and leaving both carboxamide moieties available. 
The biological activities of all these complexes were not investigated. It can be seen from 
literature review that there is little or no work carried out on investigation of biological 
activities by many researchers. Attempt was made by our research group to investigate 
antimicrobial activities of vitamin-metal complexes. Investigation of antimicrobial activities 
of transition metal complexes of vitamin C was carried out. Obaleye et al. (1994) ; Obaleye 
and Ojiekwe, (1983) synthesized and screening Co(II), Zn(II), Mn(II),Fe(III),Hg(II),Cu(II) and 
Cd(II) complexes of vitamin C against four strains of bacterial species- Escherichia coli, 
Klebbsiella pneumonia, staphylococcus aureus and Bacillus substilis and two fungal species- 
Aspergillus flavus and Aspergillus niger. The complexes have little or no activity on the 
bacterial species studied. Generally, percentage inhibition of Ascorbic acid on fungal species 
was the greatest among all compounds tested.  
10. Antidote 
Metal complexes have been used as antidote since 1945, for chronic intoxication arising from 
therapy or household contamination or hasten excretion of radioactive element. These 
antidotes circulate in the blood stream without causing much depletion of the body ’s 
essential metals. A lot of ligands have been used as antidote to combat metal poisoining. 
Dimercaptol is used to counter poisoning by compound of gold and mercury. The use of 
ascorbic acid as a possible antidote was demonstrated by Key pour et al. (1986). 
In an attempt to discover possible antidote for drug or metal poisoning. We investigated the 
interaction of pyrimidine and sulphonamide drugs with some transition metals by determining 
their stability constants in order to assess their potentiality as antidote for metal-overload 
poisoning(Tella and Obaleye, 2010). The stability constant(β) were found to be log 10.68, 5.5 and 
4.8 for Trimethoprim, sulphadiazine and sulphadimidine with respect to metal salts. The order 
of stability constants(β) was found to be Cu(II) > Fe(III).>Ni(II) >Co(II) > Zn(II) in accordance 
with Irvin-williams series. The stability constant data revealed that this ligand may be used as 
antidote or chelating agent for medical treatment of metals overload or poisoning. 
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11. Conclusion 
The structure of known biologically active molecules is modified to result in new molecules 
known as metal coordinated complexes. The goal of such modification is to get a molecule 
that is improved in some way, such as potency, stability, reduced side effect or targeted 
delivery. The improvement is achieved without sacrificing the molecules’ desirable 
properties. In this paper, we have been able to shield light on effort made so far by our 
group and other researchers in discovery of new antibacterial agents by modification of 
existing known biological agents through the incorporation of metal into their molecular 
structure. We have been able to establish that some of these complexes are biologically 
active than their parent ligands, making them promising candidates to join league of metal-
based drugs already in market. It should be known that traditional studies of organic drugs 
at a fundamental level are not complete without a parallel program on metal pharmacology. 
ln general, because metal can undergo ligand exchanges, metal complexes are pro-drugs, 
ligand substitution can activate the metal complex toward binding to target molecules.  
It should be recognized that a metal is not just a metal : it is a metal ion plus its ligand. The 
metal ion plus the ligand determine the biological activity. 
We should know that despite the obvious success of metal complexes (Cisplatin, 
Silverderma, Flammazine and others) as chemotherapeutic agents, few pharmaceutical 
companies have serious in-house research programs that address these important 
bioinorganic aspects of medicine. Research programs in organic and metallo-drugs should 
not be seen as mutually exclusive. They overlap extensively and the combination is likely to 
be a powerful force for the future. 
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